President Nana Addo Dankwa Akufo-Addo has provided details on Ghana’s decision to accept a new malaria vaccine developed by Oxford University scientists.
The malaria vaccine R21, which will be given to infants and children up to the age of three, will aid in the fight against malaria, which has become a fatal disease among youngsters.
President Akufo-Addo stated during the inauguration of the DEK Manufacturing Plant in Accra that the government approved the vaccination because it has been proven to be safe.
“The approval was granted following an extensive series of reviews and further peer reviews of the non-clinical and clinical quality parts of the vaccines. The R21 malaria vaccine has been approved for use for the immunisation of children between 5 months and 36 months against malaria,” President Akufo-Addo explained.
Oxford University developed the vaccine, which was manufactured by the Serum Institute of India.
The Food and Drug Authority (FDA) announced that it has granted market authorization to R21, a novel malaria vaccine regarded as a “world changer.”
The FDA stated that after a thorough examination of the vaccine’s quality, efficacy, and safety, it determined that the benefits clearly outweighed the dangers.
